dr. bazhenova on prevalence of ntrk mutations in nsclc
Published 6 years ago • 309 plays • Length 1:25Download video MP4
Download video MP3
Similar videos
-
1:42
dr. bazhenova on sequential use of immunotherapy and egfr tkis in lung cancer
-
1:58
dr. bazhenova on sequencing beyond progression in egfr-mutant nsclc
-
0:51
dr. bazhenova on ongoing clinical trials with immunotherapy in nsclc
-
7:09
the ntrk family of fusions in nsclc
-
2:00
dr. bazhenova on new developments in ret-rearranged nsclc
-
13:43
fda approvals in ntrk fusion tumors, ros1 nsclc, and myelofibrosis, and more
-
5:01
ntrk gene fusions in nsclc
-
1:08
dr. bazhenova on the pacific trial with durvalumab in nsclc
-
1:14
dr. bazhenova on the value in attending onclive state of the science summits
-
6:59
other targeted approaches in nsclc: ntrk or ret fusions
-
1:36
dr. drilon on ntrk rearrangement in lung cancer
-
1:17
dr. bazhenova on the potential approval of lorlatinib for patients with alk-positive nsclc
-
7:14
larotrectinib for solid tumors with ntrk gene fusions
-
2:39
ntrk gene fusions: rare yet actionable
-
5:49
targeting her2 mutations in nsclc: what do we know?
-
2:17
dr. paz-ares on entrectinib in ntrk fusion-positive nsclc
-
5:15
role of ntrk inhibitors
-
1:47
dr. paik on resistance mutations in nsclc
-
14:30
the detection of ntrk gene fusions in nsclc